CATALENT, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 55.81 USD | -0.30% |
|
-1.22% | +24.22% |
| 05-09 | MOVES -Lazard hires veteran healthcare dealmaker Colocci as vice chairman | RE |
| 05-08 | Earnings Flash (CTLT) CATALENT Posts Q3 Revenue $1.07B | MT |
Presenter SpeechElaine Quilici (Analysts)Hello, again, everyone. If this is your first session...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Catalent, Inc. is specialized in pharmaceutical outsourcing services. The group offers solutions for the development and formulation of drugs, biological products and animal health products. Net sales break down by activity as follows:
- provision of development services and clinical supply services (55.4%);
- subcontracted manufacturing services (44.6%).
Net sales are distributed geographically as follows: the United States (63.2%), Europe (28.7%) and other (8.1%).
Sector
Pharmaceuticals
Calendar
28/05/2024
- Extraordinary Shareholders Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
55.81
USD
Average target price
63.5
USD
Spread / Average Target
+13.78%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +24.22% | 10.1B | |
| +30.38% | 684B | |
| +26.51% | 568B | |
| -4.36% | 361B | |
| +19.30% | 329B | |
| +3.73% | 284B | |
| +16.70% | 240B | |
| +8.78% | 208B | |
| -7.93% | 200B | |
| +7.68% | 166B |
- Stock Market
- Equities
- CTLT Stock
- News Catalent, Inc.
- Transcript : Catalent, Inc. Presents at 2021 Biopharma CEO Investor Forum, Jun-08-2021 09
